IL-6 detection in multiple sclerosis brain

被引:135
|
作者
Maimone, D [1 ]
Guazzi, GC [1 ]
Annunziata, P [1 ]
机构
[1] UNIV SIENA,INST NEUROL SCI,I-53100 SIENA,ITALY
关键词
interleukin-6; multiple sclerosis; central nervous system; astrocyte;
D O I
10.1016/S0022-510X(96)00283-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
By using a double-label immunohistochemistry technique, we demonstrated the presence of interleukin-6 (IL-6) in acute and chronic active plaques from the brain of six patients with multiple sclerosis (MS). IL-6 was mainly associated with astrocytes and rarely with macrophages or mononuclear infiltrating cells. The pattern of distribution for IL-6 immunoreactivity was similar to that of HLA-DR expression, but the two molecules almost never colocalized on the same cell. Our data indicate that in MS central nervous system IL-6 is predominantly located within resident glial cells which are concentrated at the sites of ongoing demyelination and immune activation. Although IL-6 exhibits several proinflammatory activities, indirect evidence suggests that the cytokine may also play an immunomodulatory role in inflammatory demyelinating disorders. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [31] Interleukin-6 (IL-6) production by astrocytes: Autocrine regulation by IL-6 and the soluble IL-6 receptor
    Van Wagoner, NJ
    Oh, JW
    Repovic, P
    Benveniste, EN
    JOURNAL OF NEUROSCIENCE, 1999, 19 (13): : 5236 - 5244
  • [32] IL-17, IL-6 and IFN-gamma in systemic sclerosis patients
    Balanescu, P.
    Ladaru, Anca
    Balanescu, Eugenia
    Nicolau, Adriana
    Baicus, C.
    Dan, Gh. A.
    ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2015, 53 (01) : 46 - 51
  • [33] Soluble IL-6 receptor synergistically stimulates the growth of multiple myeloma with IL-6 and confers resistance to bortezomib.
    Lee, Young Y.
    Park, Joowon
    Yoon, Sung-Soo
    Choi, Jung H.
    Park, Byoung B.
    Kim, Byoung K.
    BLOOD, 2007, 110 (11) : 258B - 258B
  • [34] DETECTION OF SERUM IL-6 IN PATIENTS WITH DIABETIC NEPHROPATHY
    SEKIZUKA, K
    TOMINO, Y
    SEI, C
    KURUSU, A
    TASHIRO, K
    YAMAGUCHI, Y
    KODERA, S
    HISHIKI, T
    SHIRATO, I
    KOIDE, H
    NEPHRON, 1994, 68 (02): : 284 - 285
  • [35] Blockade of interleukin-6 (IL-6) triggered MAPK signaling cascade in IL-6 independent multiple myeloma (MM) cells
    Ogata, A
    Chauhan, D
    Urashima, M
    Teoh, G
    Treon, S
    Anderson, K
    BLOOD, 1996, 88 (10) : 408 - 408
  • [36] IL-6 polymorphism, anti-IL-6 therapy and animal models of multiple myeloma
    Jeffery, R
    Mitchison, NA
    CYTOKINE, 2001, 16 (03) : 87 - 87
  • [37] Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling
    Baran, Paul
    Nitz, Rebecca
    Groetzinger, Joachim
    Scheller, Juergen
    Garbers, Christoph
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (21) : 14756 - 14768
  • [38] IL-6 Signaling As a Potential Therapeutic Target In Relapsing-Remitting Multiple Sclerosis with An Increased Plasmablast Frequency
    Nakamura, M.
    Matsuoka, T.
    Araki, M.
    Lin, Y.
    Ssto, W.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Aranami, T.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 922 - 922
  • [39] IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
    Petrzalka, Marko
    Meluzinova, Eva
    Libertinova, Jana
    Mojzisova, Hana
    Hanzalova, Jitka
    Rockova, Petra
    Elisak, Martin
    Kmetonyova, Silvia
    Sanda, Jan
    Sobek, Ondrej
    Marusic, Petr
    PLOS ONE, 2022, 17 (06):
  • [40] Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis
    Angelucci, F
    Mirabella, M
    Caggiula, M
    Frisullo, G
    Patanella, K
    Sancricca, C
    Nociti, V
    Tonali, PA
    Batocchi, APB
    PEPTIDES, 2005, 26 (11) : 2289 - 2293